论文部分内容阅读
目的观察米氮平联合右佐匹克隆治疗慢性失眠伴发抑郁患者的临床疗效和安全性。方法将80例慢性失眠伴发抑郁的患者随机分成对照组和治疗组,各40例,对照组单用右佐匹克隆,治疗组应用米氮平联合右佐匹克隆。分别于治疗前和治疗后8周对两组患者进行匹茨堡睡眠质量指数量表(PSQI)评分及汉密尔顿抑郁量表(HAMD)评分,以PSQI减分率来评定治疗有效率。结果治疗组治疗后的HAMD及PSQI评分均低于对照组,差异有统计学意义(P<0.05),治疗组睡眠改善的有效率高于对照组,差异有统计学意义(P<0.05)。结论对于慢性失眠伴发抑郁患者,应用米氮平联合右佐匹克隆治疗能更有效的改善睡眠和抑郁状态。
Objective To observe the clinical efficacy and safety of mirtazapine and dexrazoxane in patients with chronic insomnia complicated by depression. Methods Eighty chronic insomnia patients with depression were randomly divided into control group and treatment group, 40 cases in each group. The control group was treated with dexrazoxane alone. The treatment group was treated with mirtazapine and dexrazoxane. The Pittsburgh Sleep Quality Index Scale (PSQI) and Hamilton Depression Rating Scale (HAMD) were scored before treatment and 8 weeks after treatment, and the treatment efficiency was evaluated by PSQI reduction rate. Results The scores of HAMD and PSQI after treatment in the treatment group were lower than those in the control group (P <0.05). The effective rate of sleep improvement in the treatment group was higher than that in the control group (P <0.05). Conclusion In patients with chronic insomnia with depression, the application of mirtazapine and dexrazoxane can effectively improve sleep and depression.